26 October 2005

Barry Marshall Wins Nobel Prize for H. Pylori

In honor of Drs. Marshall and Warren, I am tempted to celebrate by drinking a beaker full of H. Pylori (as Barry Marshall did over 20 years ago) followed by eliminating the infection with the F165 program below. See my previous comments on Dr. Marshall.

Nobel for stomach ulcer discovery

Stomach ulcer
Stomach ulcers can be treated with antibiotics
Two Australian scientists have been awarded the
Nobel prize for medicine for their discovery that stomach ulcers can be caused by a bacterial infection.

BBC News, 3 October 2005

Robin Warren and Barry Marshall showed the bacterium Helicobacter pylori plays a key role in the development of both stomach and intestinal ulcers.
Thanks to their work these ulcers are often no longer a long-term, frequently disabling problem. They can now be cured with a short-term course of drugs and antibiotics.
In 1982, when H. pylori was discovered by Dr Marshall and Dr Warren, stress and lifestyle were considered the major causes of stomach and intestinal ulcers. It is now firmly established that the bacterium causes more than 90% of duodenal (intestinal) ulcers and up to 80% of gastric (stomach) ulcers.
Dr Warren, a pathologist from Perth, paved the way for the breakthrough when he discovered that small curved bacteria colonised the lower part of the stomach in about 50% of patients from which biopsies had been taken._________
Version 1.0 of the H. Pylori Programs Released

By popular request separate H. Pylori programs have been generated for the F165, F160, F155, and F150 frequency generators using the appropriate scalar octaves. This will allow researchers with Rife devices that only go up to 10,000hz to easily apply these frequencies.

All frequencies developed during the past decade are now posted on a subscribers blog, including the latest H. Pylori frequencies and organisms commonly associated with H. Pylori. For a user name and password, sign up for a Frequency Foundation subscription with the link on the side of this web page.








16 October 2005

Update on Nanobacteria

The Nanobacteria Link
to Heart Disease and Cancer

Nanoparticles are implicated in the harmful calcification that's common to many illnesses. A simple treatment is now reversing the symptoms, especially in heart disease, so why aren't the health authorities telling patients and doctors about it?


Extracted from Nexus Magazine, Volume 12, Number 5 (August - September 2005)
by Douglas Mulhall © May–July 2005

Millions of seriously ill patients are unaware that heart disease is being measurably reversed with an approach pioneered by researchers at the National Aeronautics and Space Administration (NASA) and in Finland, aided by Mayo Clinic and Washington Hospital Center findings. This approach is now prescribed by hundreds of doctors for thousands of patients. A similar approach has been developed with prostate disease at the renowned Cleveland Clinic in Florida. According to doctors, both approaches are practical options for those whose other medicines and surgery have failed. So why aren't other desperately ill patients whose treatments don't work being told about it?

In July 2004, the medical journal Pathophysiology published a peer-reviewed research paper with the innocuous title "Calcification in coronary artery disease can be reversed by EDTA–tetracycline long-term chemotherapy".1 In plain terms, it meant that hardening of the arteries was being reversed. Not only were rock-hard calcium deposits being reduced, but chest pains were being resolved in most patients and bad cholesterol levels were being cut beyond what other medicines had achieved. The findings were important for patients whose other drugs and surgery weren't working, i.e., the "cardiac cripples", whose numbers are in the millions and whose doctors have told them there is nothing more to be done. They were the ones who responded most favourably to the new approach.

Then, in February 2005, a paper published in the prestigious Journal of Urology by researchers from the Cleveland Clinic, one of the leading urology hospitals in America, reported "significant improvement" in chronic prostatitis—a growing problem for millions of men—again, where other approaches had failed.

The studies, although otherwise separate, had a compelling link. They used a cocktail of well-known, inexpensive medicines that have been around for half a century but were never before used in this combination. Both reports urged more studies to confirm their conclusions, and emphasised that not every patient experienced a reversal; only a majority did. Nonetheless, the results were encouraging. Chronic diseases that had befuddled modern medicine were being reversed.

To put a human face on this, take the case reported by Dr Manjit Bajwa of McLean, Virginia, who did not participate in the clinical studies but whose experience with one patient paralleled study results. Dr Bajwa reported in a testimonial of 5 May 2005:

"Two years ago I had a patient with severe coronary artery disease with a 75–85% blockage in left coronary and two other arteries. Open heart surgery was recommended as stents could not be put in. The patient was told he would probably die within two weeks if surgery was not performed.

"He declined surgery and instead chose chelation. [Author's note: chelation in this case is an intravenous form of heavy metal removal.] After twenty-five treatments of chelation, his angina worsened [author's emphasis]. With [his] heart calcium score of 2600, I started the nanobacteria protocol. Within two to three weeks his angina abated. He was able to return to all his normal activities and exercises in two months.

"Nanobacteria protocol helped this patient measurably, when other treatments had failed. I am quite impressed with his results. With heart calcium scores of 750 or more, nothing else seems to work."



I've reported on nanobacteria previously. Frequency sets should always be used in combination with oral or IV chelation therapy. In addition, nanobacteria reinfection is common so periodic elimination is required.

The previous frequency reported had some Lyme frequencies, particularly in the 500-700khz range. This is because over 80% of the people I test have at least a light Lyme infection. As I now have a comprehensive set of six different programs for use in eliminating Lyme organisms, I have removed Lyme frequencies from the nanobacteria set. It should be noted that many humans or animals with a heavy nanobacteria infection will have a concurrent Lyme infection that needs to be addressed.

Nanobacteria frequencies are regularly updated and now available to Frequency Foundation subscribers. See link on side of page to sign up.

11 October 2005

Bacterial Infections: A Quarter of all Deaths and Rising

I've reported before on evolutionary biology and how important and rare it is to inject this thinking into medicine and public health. Frequency research can be used to target specific bacteria for elimination mimicking the strategies now being used in antibiotic research.

Battling Evolution to Fight Antibiotic Resistance

For any new antibiotic, resistant bacteria typically show up in four years, or less. Penicillin resistance was reported clinically even before large-scale use of the antibiotic began in 1942. The battle against antibiotic-resistant bacteria demands new drugs and smarter, more responsible ways to use existing ones. Some researchers, however, are pursuing another type of weapon: drugs that sidestep natural selection. Less virulent bacteria would decrease the need for antibiotics, some reason, and drugs that drastically slow mutation rates might cut off evolution's power source.

Evaluating nonkilling approaches in the lab and clinic is tricky, and outfoxing evolution in the real world could prove even more difficult. Bacteria have evolved their way past ostensibly impenetrable barriers a number of times. Still, even if new approaches only hold off the inevitable, they could be a big win. "Half a loaf is better than none," says Abigail Salyers, professor of microbiology at University of Illinois Urbana-Champaign. Moreover, since microbe defenses develop so quickly, staying ahead of these pathogens requires more than new drugs that kill bacteria in new ways.

02 October 2005

Kikuchi's Disease and Parvovirus B19

Kikuchi's disease is associated with benign lymphatic tumors which can be mistaken for lymphoma. It has been associated with Parvovirus B19 (see photo from New York State Dept. of Health). It's frequency is close to that of the Epstein Barr virus so symptoms may be mistaken for mononuclosis.

This is quite a nasty virus and difficult to eliminate. Any virus will alter cells to become factories for producing the virus so targeting malfunctioning cells is important.

Researchers may want to try the following F165 program as it may be useful in eliminating Parvovirus B19. I'm interested in hearing about any success with this frequency program.

repeat 40
dwell 360
program a
vbackfreq b 0.002478752 0 66.6 #scalar octave
converge .016% 1
4444343 #aberrated cells
vbackfreq b 0.049787068 0 66.6 #scalar octave
converge .044% 1
344777 266780 156666 66666 15544 #Parovirus B19
end repeat